Genelux (GNLX) Asset Utilization Ratio (2023 - 2024)
Genelux (GNLX) posted quarterly Asset Utilization Ratio of 0.0 for Q4 2024, down 96.11% year-over-year from 0.01 in Q1 2024, and up 13.95% quarter-over-quarter from 0.0 in Q3 2024.
Genelux (GNLX) Asset Utilization Ratio (2023 - 2024) Analysis & Trends
Genelux's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q4 2024.
- In Q4 2024, Asset Utilization Ratio fell 96.11% year-over-year to 0.0; the TTM figure through Dec 2024 stood at 0.0 (down 96.11% YoY), while the FY2025 annual figure was 0.0, up 16.5% from the prior year.
- Asset Utilization Ratio for Q4 2024 stood at 0.0, up from 0.0 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.01 in Q4 2023, with the low at 0.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.01 |